Deborah Nahas

Mrs. Deborah Nahas


Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2016 in Vaccine
Verified
Journal Article
Closed access
Donald ChabotDonald Chabot
Donald Chabot
WRWilson J. Ribot
Wilson J. Ribot
JJJoseph Joyce
Joseph Joyce
JCJames Cook
James Cook
RHRobert Hepler
Robert Hepler
AFArthur M. Friedlander
Arthur M. Friedlander

12 December 2007 in Bioconjugate Chemistry
Verified
Journal Article
Closed access
DNDeborah Nahas
Deborah Nahas
JPJennifer S. Palladino
Jennifer S. Palladino
JJJoseph G. Joyce
Joseph G. Joyce
RHRobert W. Hepler
Robert W. Hepler

13 January 2026 in Pathogens
Verified
Journal Article
Open access
PDF file
RPRuchin Patel
Ruchin Patel
EMEdward Murray
Edward Murray
DNDeborah Nahas
Deborah Nahas
MYMahdieh Yazdani
Mahdieh Yazdani
BABrett Robert Ambler
Brett Robert Ambler
JHJohn A. Howe
John A. Howe
Respiratory syncytial virus (RSV) remains a leading cause of lower respiratory tract infections (LRTIs) and infant mortality worldwide. Despite recent advances in prophylactic interventions, effective therapeutics for active RSV infection are still lacking. Small molecule non-nucleoside inhibitors (NNIs) targeting the RSV L protein, particularly its polyribonucleotidyltransferase (PRNTase) domain, represent a promising antiviral strategy. Here, we evaluate the genetic variability of the PRNTase domain and the binding pocket of two NNIs, MRK-1 and MRK-2, to assess the potential for preexisting resistance. A comprehensive analysis of 28,140 RSV L protein sequences from NCBI Virus and GISAID EpiRSV databases revealed low overall variability within the PRNTase domain and near-complete conservation of the MRK-1/2 binding pocket. Resistance-associated mutations identified through in vitro dose-escalation studies localized to this pocket but were absent in global sequence datasets. These findings support the PRNTase domain as a genetically stable and viable target for NNI-based RSV therapeutics and suggest a low likelihood of preexisting resistance among circulating strains.